4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
$13.33 0.63 (4.9606%)
Analysed 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) News Sources
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
13-08-2026
yahoo.com
4DMT to Host Investor Day on October 21, 2026
05-10-2026
yahoo.com
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29-06-2026
yahoo.com
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
13-08-2026
yahoo.com
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
17-08-2026
stocktwits.com
4DMT to Participate in Upcoming Investor Conferences
25-08-2026
yahoo.com
4DMT Announces New Employment Inducement Grants
11-09-2026
yahoo.com
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28-09-2026
yahoo.com
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
28-09-2026
stocktwits.com
This is the top biotech stock pick from B Riley Securities
29-09-2026
yahoo.com
What is the current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The current price of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is $13.33.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) absolute price change since previous trading day?
The absolute price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is $0.63.
4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) percentage price change since previous trading day?
The percentage price change of 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) since the previous trading day is 4.9606%.
What is the most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent average sentiment score for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)?
The most recent sentiment for 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ) is .
SEC-8K** Filing Available For 4D MOLECULAR THERAPEUTICS IN (FDMT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.